$XBI $127 -1%
Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!
Covid Updates
$BNTX +3% pdate on Stability of COMIRNATY®: Longer Storage Possible. source
$HGEN +6% Humanigen and Chime Biologics Enter Into Manufacturing Agreement for COVID-19 Therapeutic Candidate Lenzilumab. source
Pipeline Updates
$ACIU +7% AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update. source
$ESPR -9% Simulation Model based on Pooled Phase 3 Data Demonstrating NEXLETOL® (bempedoic acid) Tablet’s Potential to Lower Absolute Cardiovascular Event Risk Presented at ACC.21. source
$PHAS +6% PhaseBio Highlights Real-World Bleeding and Surgery Data Featured at The American College of Cardiology's 70th Annual Scientific Session. source
$AMRN -1% Amarin Highlights Multiple Scientific Findings for VASCEPA® (Icosapent Ethyl) and Its Unique Active Ingredient at the American College of Cardiology’s 70th Annual Scientific Session. source
$IBRX +10% FDA Authorizes ImmunityBio to Conduct a Trial of its First-in-Human, Cryopreserved, Memory Cytokine-Enriched NK Cell (m-ceNK) Platform in Solid Tumors. source
$DMAC +6% DiaMedica Therapeutics Announces FDA Clearance of IND Application to Initiate Phase 2/3 Clinical Trial for DM199 for Acute Ischemic Stroke.
$EVFM +2% New Data on EVO100 for the Prevention of Chlamydia and Gonorrhea in Women to be Presented at ISPOR 2021. source
$CYTK -1% Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology.
$ADMP +7% Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose. source
$MIST +1% Milestone Pharmaceuticals Announces Late-Breaker Oral Presentation of NODE-301 Data at ACC.21. source
$GRTX +2% Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer. source
$FHTX -1% Foghorn Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Program of FHD-286. source
$SEEL -24% Seelos Announces Positive Topline Data from the Study of SLS-002 Demonstrating a Significant Treatment Effect and a Well Tolerated Safety Profile.
Finance Updates
$EVFM +2% Evofem Biosciences Announces Proposed Public Offering. source
$MIST +1% Milestone Pharmaceuticals Announces Exclusive License Agreement with Ji Xing Pharmaceuticals to Develop and Commercialize Etripamil for PSVT in Greater China. source
$CLVS -4% Clovis Oncology Announces At-The-Market Equity Offering Program. source
$CNCE +2% Concert Pharmaceuticals Announces Sale of VX-561 Milestones to Vertex for $32 Million. source
$LABP +1% Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets. source
Posted by DV